Arthritis By The Numbers - 1 - TABLE OF CONTENTS Introduction ......................................................................................................... 4 Section 1: General Arthritis Facts .......................................................................... 7 o Human and Economic Burdens ....................................................................................................8 - Economic Burdens ....................................................................................................................8 - Employment Impact and Medical Cost Burden .....................................................................9 Section 2: Osteoarthritis (OA) ............................................................................... 12 o Prevalence ......................................................................................................................................14 - US General Population ............................................................................................................14 - U.S. Military Prevalence ..........................................................................................................14 - Global Prevalence ....................................................................................................................15 o Human and Economic Burdens ....................................................................................................15 - Health Burdens .........................................................................................................................15 - Economic Burdens ....................................................................................................................17 - Knee, Hip and Shoulder OA Burden ......................................................................................17 - Global Burden ..........................................................................................................................19 Section 3: Autoimmune and Inflammatory Arthritis .............................................. 21 •Rheumatoid Arthritis (RA) ..................................................................................... 23 o Prevalence .....................................................................................................................................23 o Human and Economic Burdens ....................................................................................................23 - Health Burdens .........................................................................................................................23 - Work/Employment Impact ......................................................................................................23 - Medical/Cost Burdens ............................................................................................................24 •Systemic Lupus Erythematosus (SLE or Lupus) ........................................................ 25 o Prevalence .....................................................................................................................................25 o Human and Economic Burdens ....................................................................................................26 - Comorbidities and Health Burdens .........................................................................................26 - Pregnancy Impact .....................................................................................................................27 - Work/Employment Impact ......................................................................................................27 - Medical/Cost Burdens ............................................................................................................27 •Sjögren’s Syndrome .............................................................................................. 30 o Prevalence (Primary Sjögren’s Syndrome) ..................................................................................30 o Comorbidities (Secondary Sjögren’s Syndrome) ........................................................................30 o Human and Economic Burdens ....................................................................................................30 - Health Burdens .........................................................................................................................30 - Work/Employment Impact ......................................................................................................33 - Medical/Cost Burdens ............................................................................................................33 •Adult-onset Scleroderma ....................................................................................... 34 o Prevalence ......................................................................................................................................34 o Human and Economic Burdens ....................................................................................................34 - Health Burdens .........................................................................................................................34 - Economic Burdens ....................................................................................................................35 Arthritis Foundation •Spondyloarthritis (SpA) ......................................................................................... 36 o Prevalence .....................................................................................................................................36 o Human and Economic Burdens ....................................................................................................36 •Psoriatic Arthritis (PsA) .......................................................................................... 37 o Prevalence ......................................................................................................................................37 o Human and Economic Burdens ....................................................................................................37 - Health Burdens .........................................................................................................................37 - Economic Burdens ....................................................................................................................38 Section 4: Juvenile Idiopathic Arthritis (JIA) and Other Childhood Rheumatic Diseases ............................................. 40 •Juvenile Idiopathic Arthritis (JIA) ........................................................................... 42 o Prevalence .....................................................................................................................................42 o Human and Economic Burdens ....................................................................................................42 - Health Burdens .........................................................................................................................42 - Mental Health Impact ..............................................................................................................43 - School and Social Impact ........................................................................................................43 - Economic Burdens ....................................................................................................................43 •Juvenile-onset Scleroderma .................................................................................. 45 o Prevalence .....................................................................................................................................45 o Health Burdens ...............................................................................................................................45 •Juvenile Myositis (JM) ........................................................................................... 47 o Prevalence .....................................................................................................................................47 o Health Burdens ...............................................................................................................................47 Section 5: Gout .................................................................................................... 49 o Prevalence ......................................................................................................................................50 o Human and Economic Burdens ....................................................................................................50 - Health Burdens and Comorbidities .........................................................................................51 - Gout in Women ........................................................................................................................51 - Work/Employment Impact ......................................................................................................51 - Medical/Cost Burden ..............................................................................................................51 Section 6: Fibromyalgia ....................................................................................... 53 o Prevalence ......................................................................................................................................55